Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 858-863

  Sjögren, Erik ^a   Nyberg, Joakim ^a   Magnusson, Mats O ^c   Lennernäs, Hans ^a   Hooker, Andrew ^a   Bredberg, Ulf ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Exprimo NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLEARANCE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; ENZYME KINETICS; METABOLIC INTRINSIC CLEARANCE; MICHAELIS MENTEN KINETICS; MOLECULAR STABILITY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SIMULATION;

COMPUTER SIMULATION; DRUG DISCOVERY; DRUG STABILITY; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RESEARCH DESIGN;

EID: 79955033812     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037309     Document Type: Article

References (18)

1. Bardsley WG, Wood RMW, and Melikhova EM (1996) Optimal design: A computer program to study the best possible spacing of design points for model discrimination. Comput Chem 20:145-157. (Pubitemid 126358535)
2. Beal SL (1983) Computation of the explicit solution to the Michaelis-Menten equation. J Pharmacokinet Biopharm 11:641-657. (Pubitemid 14070322)
3. Beal SL, Sheiner LB, Boeckmann A, and Bauer RJ (2009) NONMEM User's Guides (1989- 2010). Icon Development Solutions, Ellicott City, MD.
4. Di L, Kerns EH, Gao N, Li SQ, Huang Y, Bourassa JL, and Huryn DM (2004) Experimental design on single-time-point high-throughput microsomal stability assay. J Pharm Sci 93: 1537-1544. (Pubitemid 38725025)
5. Endrenyi L and Chan FY (1981) Optimal design of experiments for the estimation of precise hyperbolic kinetic and binding parameters. J Theor Biol 90:241-263. (Pubitemid 11082860)
6. Foracchia M, Hooker A, Vicini P, and Ruggeri A (2004) POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 74:29-46. (Pubitemid 38283678)
7. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112. (Pubitemid 40558152)
8. Kakkar T, Pak Y, and Mayersohn M (2000) Evaluation of a minimal experimental design for determination of enzyme kinetic parameters and inhibition mechanism. J Pharmacol Exp Ther 293:861-869. (Pubitemid 30417852)
9. Mentre F, Mallet A, and Baccar D (1997) Optimal design in random-effects regression models. Biometrika 84:429-442.
10. Murphy EF, Gilmour SG, and Crabbe MJ (2003) Efficient and accurate experimental design for enzyme kinetics: Bayesian studies reveal a systematic approach. J Biochem Biophys Methods 55:155-178. (Pubitemid 36287389)
11. Nyberg J, Karlsson MO, and Hooker AC (2009) Simultaneous optimal experimental design on dose and sample times. J Pharmacokinet Pharmacodyn 36:125-145.
12. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
13. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: Intersystem extrapolation factors. Xenobiotica 34:151-178. (Pubitemid 38299716)
14. Pronzato L and Walter E (1985) Robust experiment design via stochastic-approximation. Mathematical Biosciences 75:103-120. (Pubitemid 15541326)
15. Rodrigues AD (1997) Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharm Res 14:1504-1510. (Pubitemid 28009199)
16. Sjögren E, Lennernäs H, Andersson TB, Gråsjö J, and Bredberg U (2009) The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): Accuracy and robustness evaluated through experimental data and Monte Carlo simulations. Drug Metab Dispos 37:47-58.
17. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)- based enzyme inhibition. Eur J Pharm Sci 31:232-241. (Pubitemid 46818983)
18. Youdim KA, Atkinson AC, Patan M, Bogacka B, and Johnson PJ (2010) Potential application of D-optimal designs in the efficient investigation of cytochrome P450 inhibition kinetic models. Drug Metab Dispos 38:1019-1023.